Dan Williams welcomes news that NICE has raised the cost-effectiveness threshold for ultra-rare disease drugsDr Dan WilliamsOct 81 min readRead the article on how ultra-rare disease drugs are getting a boost from NICE guidelines here>
Drug Target Review features an insightful article by Dan Williams that explores the extraordinary achievements of AI in drug design
Technology Networks features a major interview with Dr Uwe Meya, SynaptixBio’s CMO, in which the issues around organising, funding, and conducting clinical trials for rare diseases are discussed.
Dan Williams contributes to a major article for Inside Precision Medicine, in which several US families with a child living with H-ABC discuss their journey to a diagnosis
Comments